Published in Xenobiotica on April 25, 2013
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug Metab Dispos (2015) 0.78
Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. Neuropharmacology (2015) 0.77
Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics (2014) 0.77
Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. Pharmacol Rep (2016) 0.76
Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys. Br J Pharmacol (2014) 0.76
In situ hybridization study of CYP2D mRNA in the common marmoset brain. Exp Anim (2016) 0.75
Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharm Sin B (2016) 0.75
THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem (1964) 24.57
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. J Biol Chem (1964) 8.70
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev (2005) 3.32
The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol (1979) 2.29
Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav (1991) 2.04
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther (2004) 1.90
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc (2006) 1.80
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev (2004) 1.63
Reward and the serotonergic system. Neuroscience (2010) 1.36
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci (2007) 1.31
The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol (2001) 1.30
Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci (2011) 1.28
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics (2003) 1.26
Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis (1993) 1.19
Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci (2005) 1.15
The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators. J Biol Chem (2000) 1.13
Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. Drug Metab Dispos (1976) 1.13
Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. Br J Clin Pharmacol (2004) 1.10
Rodent models of tremor. Cerebellum (2007) 1.09
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics (2001) 1.06
The pathophysiology of essential tremor. Neurology (2000) 1.06
Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl (2006) 1.04
Metabolism of debrisoquine sulphate in rat, dog and man. Xenobiotica (1976) 1.04
Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl (2000) 1.03
Fatty acid oxidation in rat brain is limited by the low activity of 3-ketoacyl-coenzyme A thiolase. J Biol Chem (1987) 1.03
Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther (2007) 0.99
Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem (2002) 0.97
Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol (2012) 0.97
Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet (2004) 0.95
Possible metabolic functions of deoxycytidine diphosphate choline and deoxycytidine diphosphate ethanolamine. J Biol Chem (1959) 0.95
Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther (2012) 0.93
A possible alarm substance in the forced swimming test. Physiol Behav (1990) 0.91
Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol (1990) 0.90
Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol (2009) 0.89
CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. Neurology (1998) 0.88
Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metab Dispos (2005) 0.87
Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos (2011) 0.86
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Serotonergic contribution to boys' behavioral regulation. PLoS One (2011) 0.85
Cytochrome P450 humanised mice. Hum Genomics (2004) 0.85
Cytochrome P450 2D6 polymorphism and character traits. Psychiatr Genet (2003) 0.84
Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism. Curr Pharm Des (2007) 0.82
Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice. J Inherit Metab Dis (2010) 0.82
Statistical analysis of the processes controlling choline and ethanolamine glycerophospholipid molecular species composition. PLoS One (2012) 0.81
Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice. Pharmacol Biochem Behav (2011) 0.80
Removal of the inferior olive abolishes myoclonic seizures associated with a loss of olivary serotonin. Neuroscience (1998) 0.80
A technique for the collection of cerebrospinal fluid from mice. Lab Anim Sci (1988) 0.80
Harmaline-induced tremor and impairment of learning are both blocked by dizocilpine in the rabbit. Brain Res (1997) 0.80
Significance of central noradrenergic system on harmaline induced tremor. Pharmacol Biochem Behav (1979) 0.79
A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics (1997) 0.79
1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Drug Metab Dispos (1998) 0.79
Swimming rats and human depression. Nature (1978) 0.79
Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behav Brain Res (2003) 0.78
Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Br J Clin Pharmacol (2004) 0.78
Personalized treatment with atypical antipsychotic medications. Adv Ther (2007) 0.78
No association between CYP2D6 polymorphisms and personality trait in Japanese. Br J Clin Pharmacol (2007) 0.77
Assignment of AR1, transcription factor 20 (TCF20), to human chromosome 22q13.3 with somatic cell hybrids and in situ hybridization. Cytogenet Cell Genet (1998) 0.77
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. NIDA Res Monogr (1997) 0.76
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem (2004) 4.10
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther (2004) 3.49
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Nicotine-dependence symptoms are associated with smoking frequency in adolescents. Am J Prev Med (2003) 2.71
Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology (2003) 2.70
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology (2012) 2.62
Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab (2008) 2.57
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 2.41
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics (2004) 2.37
Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 2.35
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 2.30
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27
Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev (2006) 2.23
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther (2006) 2.21
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet (2008) 2.12
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst (2011) 1.97
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem (2002) 1.97
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther (2005) 1.96
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav (2008) 1.90
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84
The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics (2006) 1.83
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med (2008) 1.76
Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol (2011) 1.76
Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol Cell Biol (2003) 1.75
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab (2005) 1.72
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med (Berl) (2005) 1.71
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol (2005) 1.71
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 1.70
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest (2010) 1.70
Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol (2008) 1.69
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest (2008) 1.68
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med (2013) 1.67
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab (2008) 1.67
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab (2008) 1.65
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal (2005) 1.64
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev (2004) 1.63
PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol (2007) 1.62
Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther (2008) 1.62
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem (2002) 1.60